Pharma-Bio Serv (PBSV) Cost of Revenue (2010 - 2026)

Pharma-Bio Serv (PBSV) has 16 years of Cost of Revenue data on file, last reported at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 7.67% year-over-year to $1.6 million; the trailing twelve-month figure through Jan 2026 stood at $6.0 million (down 13.01% YoY), and the FY2025 full-year result was $6.1 million, down 12.9% from the prior year.
• Cost of Revenue for Q1 2026 stood at $1.6 million, up from $1.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $3.8 million in Q1 2022 and bottomed at $1.4 million in Q3 2025.
• The 5-year median for Cost of Revenue is $1.8 million (2024), against an average of $2.4 million.
• The widest annual swing landed in 2022, when Cost of Revenue advanced 18.95%; it then sank 45.31% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $3.5 million in 2022, then slipped by 24.4% to $2.7 million in 2023, then tumbled by 39.79% to $1.6 million in 2024, then declined by 12.82% to $1.4 million in 2025, then advanced by 12.27% to $1.6 million in 2026.
• The last three Cost of Revenue figures came in at $1.6 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.

Peer Comparison